EUVIMEDEUVIMED entdecken
Crossref

1694-P: Expression of GLP-1R and GIPR in Papillary and Medullary Thyroid Carcinoma and Hashimoto’s Thyroiditis: An Immunohistochemistry H-score Study

PANTELITSA RAKITZI, KIRIAKOS HATZOPOULOS, ELENI MANTHOU, THEOCHARIS KOUFAKIS, KONSTANTINOS SAPALIDIS, KALLIOPI KOTSA

Diabetes · 05.06.2026 · 75 (Supplement_1)

DOI: 10.2337/db26-1694-p ↗

Kurz gefasst

Fachartikel in der Zeitschrift Diabetes, erschienen am 05.06.2026. Verfasst von PANTELITSA RAKITZI und 5 weiteren Autor:innen.

AbstractBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Introduction and Objective: Incretin receptor (GLP-1R and GIPR) expression in thyroid pathology is clinically relevant given expanding use of incretin-based therapies. This study assessed GLP-1R and GIPR expression in papillary thyroid carcinoma (PTC), medullary thyroid carcinoma (MTC), Hashimoto’s thyroiditis (HT), and non-neoplastic thyroid tissue.

Methods

Twenty-nine thyroid tissue samples were analyzed: PTC (n=9), MTC (n=4), HT (n=8), and non-neoplastic adjacent thyroid tissue from PTC cases (n=8). Immunohistochemistry was performed using pancreatic tissue as positive control; receptor expression was semi-quantified with H-score (0-300). Group comparisons used ANOVA with Bonferroni post-hoc testing.

Results

GLP-1R showed strong, homogeneous overexpression in MTC (mean H-score 300/300) versus low-to-moderate, heterogeneous expression in PTC (60.0), HT (57.1), and non-neoplastic tissue (131.4), with significant between-group differences (p<0.001) and MTC higher than all other groups. GIPR demonstrated low-to-intermediate expression (mean values 3.1-60.0) without significant differences among groups (p=0.122), although a trend toward higher expression in MTC was observed (Figure).

Conclusion

Marked GLP-1R overexpression in MTC suggests potential diagnostic and biological relevance, whereas GIPR did not significantly discriminate across thyroid conditions studied. Disclosure P. Rakitzi: None. K. Hatzopoulos: None. E. Manthou: None. T. Koufakis: Speaker's Bureau; Current; Novo Nordisk, Lilly, Menarini Group. Advisory Panel; Current; Roche Diabetes Care. Speaker's Bureau; Current; AstraZeneca, Boehringer Ingelheim International GmbH. K. Sapalidis: None. K. Kotsa: None.

Zitieren

APA

RAKITZI, P., HATZOPOULOS, K., MANTHOU, E., KOUFAKIS, T., SAPALIDIS, K., & KOTSA, K. (2026). 1694-P: Expression of GLP-1R and GIPR in Papillary and Medullary Thyroid Carcinoma and Hashimoto’s Thyroiditis: An Immunohistochemistry H-score Study. Diabetes, 75(Supplement_1). https://doi.org/10.2337/db26-1694-p

Vancouver

RAKITZI P, HATZOPOULOS K, MANTHOU E, KOUFAKIS T, SAPALIDIS K, KOTSA K. 1694-P: Expression of GLP-1R and GIPR in Papillary and Medullary Thyroid Carcinoma and Hashimoto’s Thyroiditis: An Immunohistochemistry H-score Study. Diabetes. 2026;75(Supplement_1). doi:10.2337/db26-1694-p

BibTeX
@article{RAKITZI2026,
  author = {RAKITZI, PANTELITSA and HATZOPOULOS, KIRIAKOS and MANTHOU, ELENI and KOUFAKIS, THEOCHARIS and SAPALIDIS, KONSTANTINOS and KOTSA, KALLIOPI},
  title = {1694-P: Expression of GLP-1R and GIPR in Papillary and Medullary Thyroid Carcinoma and Hashimoto’s Thyroiditis: An Immunohistochemistry H-score Study},
  journal = {Diabetes},
  year = {2026},
  volume = {75},
  number = {Supplement_1},
  doi = {10.2337/db26-1694-p}
}
Kostenlos starten →